Search our team at AdventHealth Research Institute
-
NCT06500273
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe study is being conducted in patients diagnosed with large B-cell lymphoma who have completed initial therapy. The study aims to see if CAR T cells made from healthy donors are an effective...
-
NCT06318273
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer
This study is currently enrolling.Research Area: Clinical Cancer ResearchThe purpose of this study is to see if the study drug is safe and tolerable.
This study will consist of 2 main phases: dose escalation (Part 1) and dose expansion (Part 2). In Part 1, multiple... -
NCT05342883
Feasibility study of resection and GammaTile followed by concomitant external beam radiation therapy (EBRT) and temozolomide (TMZ) and adjuvant TMZ in newly diagnosed glioblastoma (GBM)
This study is currently enrolling.Associated Conditions: Neuro-Interventional RadiologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research study is to evaluate the safety of GammaTile in combination with the Stupp Protocol for the treatment of newly diagnosed Glioblastoma patients. A GammaTile (GT) is an FDA...
-
NCT06238479
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchYou are being invited to take part in this study because you have been diagnosed with a type of cancer that may express a protein called nectin-4, which LY4101174 is designed to treat and you have...
-
NCT06356311
MK2870-015: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
This study is currently enrolling.Associated Conditions: Esophageal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaTo compare MK-2870 to TPC
with respect to OS.To compare MK-2870 to TPC with respect to PFS per RECIST 1.1 as assessed by BICR. To compare MK-2870 to TPC with respect to ORR per RECIST 1.1 as assessed... -
NCT06132958
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this trial is to: Test the safety of the trial drug, MK-2780: see how well the trial drug works, see how your body handles the trial drug. See how well MK-2870 works compared to the 2...
-
NCT05953337
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to evaluate the safety and effectiveness of a new medical device and how well it works for people with HCC. The new medical device is called Eye90 microspheres (Eye90)...
-
NCT06282575
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis is an open-label, randomized, multicenter, phase 3 study to investigate the efficacy and safety of zanidatamab plus CisGem with or without a PD-1/L1 inhibitor (physician’s choice of either...
-
NCT05914116
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
-
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe primary objective of the study is to demonstrate that epcoritamab
with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy
(CIT) in subjects with previously untreated FL. The primary... -
NCT05332054
Long-Term Follow-up Study (LTFS): An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaCaribou's CAR-T cell product is a genetically modified cell therapy, meaning it is designed to change the expression of a gene or alter natural properties of living cells. Healthy donor T cells have...
-
NCT06072612
A Phase 3 Randomized, Open-label Study Comparing the Bria-IMT regimen in combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research study is to assess the safety and effectiveness of an experimental therapy for advanced breast cancer called Bria-IMT (SV-BR-1-GM) in combination with the immune...